Use of ibandronate in the prevention of skeletal events in metastatic breast cancer.

Ther Clin Risk Manag · 2008 · PMC2504065 · PMID 18728841

Europe PMC DOI

hedged sentence

0.0740

closest p · 1.5× alpha

0.0740

boldest claim

The sentences

showed a trendp = 0.074so close (0.05 < p ≤ 0.1)

did not reach statistical significanceno p-value reported

A similar study with 435 patients comparing oral ibandronate 50 mg with placebo showed a trend towards improved pain scores and decreased analgesic use (p = 0.074) but did not reach statistical significance ( Tripathy et al 2004 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.